Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan in Recurrent Malignant Gliomas
NCT00003301Phase 2Completed
- Sponsor
- New Approaches to Brain Tumor Therapy Consortium
- Start
- Jul 1998
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of irinotecan in malignant glioma (2 arms), sponsored by New Approaches to Brain Tumor Therapy Consortium. Primary endpoint: Maximum Tolerated Dose. Started Jul 1998; status: completed.
02
Drugs
irinotecan
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00003301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003301.